Kalaris Therapeutics to present Phase 1a TH103 data in treatment-naive wet AMD patients at CTS 2026

Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc.

KLRS

0.00
  • Kalaris Therapeutics will present Phase 1a single-ascending-dose results for TH103 in treatment-naïve wet AMD patients on June 13, 2026.
  • The data were previously presented at Retina World Congress 2026.
  • The update highlights early clinical performance of TH103, the company’s lead retinal program, in a first-in-human setting.
  • TH103 is being advanced into a Phase 1b/2 trial in neovascular AMD, supporting continued development toward longer-acting anti-VEGF therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120800PRIMZONEFULLFEED9745960) on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.